Effect of β-lactamase detection on reducing the incidence of antibiotic-associated diarrhea in children with severe bacterial pneumonia

XIANG Yun; WANG Zai-Hua; CAI Ping; ZHANG Zhen

doi:10.7499/j.issn.1008-8830.2016.10.017

PDF(1356 KB)

Chinese Journal of Contemporary Pediatrics ›› 2016, Vol. 18 ›› Issue (10) : 1001-1004. DOI: 10.7499/j.issn.1008-8830.2016.10.017

CLINICAL RESEARCH

Effect of β-lactamase detection on reducing the incidence of antibiotic-associated diarrhea in children with severe bacterial pneumonia

XIANG Yun¹, WANG Zai-Hua², CAI Ping², ZHANG Zhen¹

Author information +

History +

Abstract

Objective To study the effect of β-lactamase (BLs) detection and β-lactam/β-lactamase inhibitor (BL/BLI) on the incidence of antibiotic-associated diarrhea (AAD) in children with severe bacterial pneumonia. Methods The clinical data of the children with bacterial severe pneumonia were retrospectively studied. Of all the patients, 248 using amoxicillin/clavulanate but without BLs detection and 323 using amoxicillin (BLs negative) or amoxicillin/clavulanate (BLs positive) were used as the amoxicillin group; 208 patients using piperacillin/tazobactam but without BLs detection and 291 patients using piperacillin (BLs negative) or piperacillin/tazobactam (BLs positive) were used as the piperacillin group; and 191 patients using cefoperazone/sulbactam but without BLs detection and 341 patients using cefoperazone (BLs negative) or cefoperazone/sulbactam (BLs positive) were used as the cefoperazone group. The incidence and clinical symptoms of AAD between the undetected and detected BLs patients were compared. Results The incidences of AAD in the amoxicillin, piperacillin and cefoperazone groups without BLs detection groups were significantly higher than those in the corresponding groups with negative or positive results of BLs detection (P < 0.01). The durations of diarrhea, antibiotic use and hospitalization stay in AAD patients receiving BLs detection were shorter than in those without receiving BLs detection (P < 0.01). Conclusions It is very important to detect BLs for reducing the incidence and relieving symptoms of AAD in children with severe bacterial pneumonia.

Key words

Severe bacterial pneumonia / Antibiotic-associated diarrhea / β-lactamase / β-lactam/β-lactamase inhibitor / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

XIANG Yun, WANG Zai-Hua, CAI Ping, ZHANG Zhen. Effect of β-lactamase detection on reducing the incidence of antibiotic-associated diarrhea in children with severe bacterial pneumonia[J]. Chinese Journal of Contemporary Pediatrics. 2016, 18(10): 1001-1004 https://doi.org/10.7499/j.issn.1008-8830.2016.10.017

References

[1] 李自华, 程国平, 汪在华, 等. 细菌性重症肺炎患儿抗生素相关性腹泻发病率及高危因素分析[J]. 临床儿科杂志, 2015, 33(8): 698-701.
[2] 中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会. 儿童社区获得性肺炎管理指南(2013 修订)( 上)[J]. 中华儿科杂志, 2013, 51(10): 745-752.
[3] 洪香华,孙自镛. 临床微生物与寄生虫病[M]//尚红, 王毓三, 申子瑜. 全国临床检验操作规程. 第4 版. 北京: 人民卫生出版社, 2015: 574-625.
[4] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-fifth informational supplement[M]. M100S25. Wayne, PA: CLSI, 2015: 108-110.
[5] 中华人民共和国卫生部. 医院感染诊断标准( 试行) [J]. 中华医学杂志, 2001, 81(5): 314-320.
[6] Luzina EV, Lareva NV. Antibiotic-associated diarrhea in clinical practice[J]. Ter Arkh, 2013, 85(2): 85-88.
[7] 鲍连生, 张振, 张多. 重症细菌性肺炎患儿继发抗生素相关性腹泻临床分析 [J]. 临床儿科杂志, 2014, 32(6): 562-563.
[8] 周华, 李光辉, 陈佰义, 等. 中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识[J]. 中华医学杂志, 2014, 94(24): 1847-1856.
[9] Rashid MU, Rosenborg S, Panagiotidis G, et al. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota[J]. Int J Antimicrob Agents, 2015, 46(1): 60-65.
[10] Dubreuil L, Odou MF. Anaerobic bacteria and antibiotics: What kind of unexpected resistance could I find in my laboratory tomorrow[J]. Anaerobe, 2010, 16(6): 555-559.
[11] Charteris WP, Kelly PM, Morelli L, et al. Antibiotic susceptibility of potentially probiotic Lactobacillus species[J]. J Food Prot, 1998, 61(12): 1636-1643.
[12] Masco L, Van Hoorde K, De Brandt E, et al. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products[J]. J Antimicrob Chemother, 2006, 58(1): 85-94.
[13] Bergogne-Bérézin E. Treatment and prevention of antibiotic associated diarrhea[J]. Intern J Antimicrob Agent, 2000, 16(4): 521-526.
[14] Toussaint KA, Gallagher JC. β-Lactam/β-Lactamase inhibitor combinations: from then to now[J]. Ann Pharmacother, 2015, 49(1): 86-98.